SCHEMBL3645598

SCHEMBL3645598

C/C=C/c1cc([N+](=O)[O-])ccc1-n1cccnc1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.38
ALDH1A1 P00352 6/20 0.38
KMT2A Q03164 3/20 0.38
TDP1 Q9NUW8 3/20 0.38
GAA P10253 2/20 0.38
POLB P06746 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
IDO1 P14902 1/20 0.37
MEN1 O00255 2/20 0.37
L3MBTL1 Q9Y468 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 1/20 0.36
HTT P42858 2/20 0.36
CASP1 P29466 1/20 0.36
CASP3 P42574 1/20 0.36
CASP4 P49662 1/20 0.36
CASP7 P55210 1/20 0.36
CASP9 P55211 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3645601 1.00 MAPT (0.38) MAPTALDH1A1KMT2ATDP1GAA
SCHEMBL9914180 0.81 L3MBTL1 (0.39) MAPTALDH1A1KMT2APOLBMEN1
SCHEMBL3639869 0.81 L3MBTL1 (0.39) MAPTALDH1A1KMT2APOLBMEN1
SCHEMBL3639871 0.81 L3MBTL1 (0.39) MAPTALDH1A1KMT2APOLBMEN1
SCHEMBL3422710 0.79 ERN1 (0.42) MAPTALDH1A1KMT2ATDP1GAA
SCHEMBL3422707 0.79 ERN1 (0.42) MAPTALDH1A1KMT2ATDP1GAA
SCHEMBL2477838 0.79 CHEK1 (0.38) MAPTALDH1A1KMT2APOLBMEN1
SCHEMBL3060321 0.79 CHEK1 (0.38) MAPTALDH1A1KMT2APOLBMEN1
SCHEMBL13272461 0.79 ERN1 (0.42) MAPTALDH1A1KMT2ATDP1GAA
SCHEMBL2474273 0.78 NR1H2 (0.36) MAPTALDH1A1KMT2AGAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198267-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
US-8198267-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
EP-2167499-A2 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF Bayer Schering Pharma AG (DE) 2010-03-31 EP disclosed
WO-2008155069-A2 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, OXA1L, PPOX MAPT 4810/4885ALDH1A1 441/4885KMT2A 3086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.